Suzhou Pharmavan

Pharmavan is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets in oncology and immunology, utilizing a structure-based drug design platform to create candidates with superior selectivity and safety profiles. Its lead program is a potent USP1 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors, particularly those with DNA damage repair deficiencies. Pharmavan aims to address significant unmet medical needs through its internal R&D capabilities and strategic collaborations within the global biotech ecosystem.